Dr. Louise Provencher is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Provencher is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Provencher is a scientific committee member at the McPeak-Sirois research group and the CHU de Quebec leader for the National Surgical Adjuvant Breast and Bowel Project.

Using structured breast cancer data

The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.

Offer innovative treatments

The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Supporting quality of life

The Centre des Maladies du Sein of CHU de Québec-University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8
+1 418-682-7511
Louise.Provencher@chudequ... louise.provencher@crchude...

Latest news

84 entries « ‹ 2 of 9 › »

Fehrenbacher L, Cecchini RS, Geyer Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2

Journal Article

J Clin Oncol, 38 (5), 2020.

Abstract | Links:

Ruel S, Ivers H, Savard MH, Gouin JP, Lemieux J, Provencher L, Caplette-Gingras A, Bastien C, Morin CM, Couture F, Savard J

Insomnia, immunity, and infections in cancer patients: Results from a longitudinal study

Journal Article

Health Psychol, 39 (5), 2020.

Abstract | Links:

Humphries B, Lauzier S, Drolet M, Coyle D, Masse B, Provencher L, Robidoux A, Maunsell E

Wage losses among spouses of women with nonmetastatic breast cancer

Journal Article

Cancer, 126 (5), 2020.

Abstract | Links:

Corter AL, Speller B, McBain K, Wright FC, Quan ML, Kennedy E, Schmocker S, Baxter NN,

Evaluating A Multidisciplinary Cancer Conference Checklist: Practice Versus Perceptions

Journal Article

J Multidiscip Healthc, 12 , 2019.

Abstract | Links:

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE,

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Journal Article

N Engl J Med, 380 (7), 2019.

Abstract | Links:

Leblond MA, Duchesne N, Provencher L, Hogue JC, Pinault S

Is contralateral breast ultrasound worthwhile in preoperative staging of breast cancer?

Journal Article

J Clin Ultrasound, 47 (4), 2019.

Abstract | Links:

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial

Journal Article

J Clin Oncol, 37 (3), 2019.

Abstract | Links:

Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L, Moisan J, Lauzier S

Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions

Journal Article

Pharmacy (Basel), 6 (2), 2018.

Abstract | Links:

Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C

Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients

Journal Article

Clin Breast Cancer, 18 (4), 2018.

Abstract | Links:

Poirier E, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J, Doyle C, Diorio C, Hogue JC, Provencher L

In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities

Journal Article

J Surg Oncol, 117 (7), 2018.

| Links:

84 entries « ‹ 2 of 9 › »
Signaler des ajouts ou des modifications

Active projects

  • A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in women with estrogen receptor-positive primary breast cancer, from 2016-03-30 to 2025-12-25
  • Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, from 2016-07-01 to 2024-09-30
  • NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
  • Omega-3 fatty acids in the prevention of breast cancer: role of obesity-related markers in breast tissues, from 2018-10-01 to 2026-09-30
  • Towards better outcomes for young women with breast cancer : A pan-canadian collaborative - Reducing the bUrden of Breast cancer in Young women (RUBY), from 2016-03-10 to 2025-12-25

Recently finished projects

  • Breast adipocyte hypertrophy: a novel biomarker to predict breast cancer survival, from 2022-01-01 to 2023-03-31
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2023-03-01
  • Utilisation de l'intelligence artificielle (IA) afin de prédire les résultats de biopsies faites pour les mammographies anormales avec comme but ultime de réduire le nombre de biopsies , from 2019-12-09 to 2021-12-08
  • Utilisation de l'intelligence artificielle afin de maintenir automatiquement le registre national de suivi en cancer du sein et du projet de recherche en cancer du sein associé, from 2019-01-01 to 2021-12-31
Data provided by the Université Laval research projects registery